Two Pfam Protein Families Characterized by a Crystal Structure of Protein lpg2210
News Sep 09, 2013

Abstract
Background
Every genome contains a large number of uncharacterized proteins that may encode entirely
novel biological systems. Many of these uncharacterized proteins fall into related sequence
families. By applying sequence and structural analysis we hope to provide insight into novel
biology.
Results
We analyze a previously uncharacterized Pfam protein family called DUF4424
[Pfam:PF14415]. The recently solved three-dimensional structure of the protein lpg2210
from Legionella pneumophila provides the first structural information pertaining to this
family. This protein additionally includes the first representative structure of another Pfam
family called the YARHG domain [Pfam:PF13308]. The Pfam family DUF4424 adopts a 19-
stranded beta-sandwich fold that shows similarity to the N-terminal domain of leukotriene A-
4 hydrolase. The YARHG domain forms an all-helical domain at the C-terminus. Structure
analysis allows us to recognize distant similarities between the DUF4424 domain and
individual domains of M1 aminopeptidases and tricorn proteases, which form massive
proteasome-like capsids in both archaea and bacteria.
Conclusions
Based on our analyses we hypothesize that the DUF4424 domain may have a role in forming
large, multi-component enzyme complexes. We suggest that the YARGH domain may play a
role in binding a moiety in proximity with peptidoglycan, such as a hydrophobic outer
membrane lipid or lipopolysaccharide.
This article was published online in BMC Bioinformatics and is free to access.
RELATED ARTICLES
Neuropeptide Y Y1 Receptor Structure Solved, Offers New Opportunities for Anti-obesity Drug Discovery
NewsScientists solve the crystal structure of Neuropeptide Y Y1 Receptor, offering new opportunities for anti-obesity drug discovery.
READ MORECrystal Structure of Neuropeptide 1 Receptor Solved, Providing Therapeutic Angle For Obesity Treatment
NewsAn international team has uncovered the potential to beat obesity at the cellular level, characterizing for the first time a complex, little-understood receptor type that, when activated, shuts off hunger.
READ MOREPhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets
NewsPhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.
READ MOREComments | 0 ADD COMMENT
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE2nd International Conference and Exhibition on Nanomedicine and Drug Delivery
May 21 - May 23, 2018
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
Login
You must be logged in to post a comment.